A new drug may be the answer for pet owners who want their dogs to live their best lives and be part of the family for as long as possible,
The veterinary medicine company, Loyal for Dogs, says after four years of testing, it has a longevity drug for dogs that has passed the first step of US Food and Drug Administration approval.
The drug, named LOY-001, is meant for dogs over 7 years old, 40 pounds or more, and would be injected by a veterinarian every three to six months. It is anticipated to be on the market by 2026.
The company's founder, Celina Halioua said her goal was to bring the first lifespan extension drug to market.
"I'm so proud to announce that Loyal has earned what we believe to be the FDA's first-ever formal acceptance that a drug can be developed and approved to extend lifespan," Halioua said.
The drug underwent a four-year testing period before the recent FDA first-step approval, according to Halioua.
Julie Sharp
Julie Sharp is a digital producer at kcalnews.com. Julie has written for The Beach Reporter covering the city of Manhattan Beach and community-based articles for the Palos Verdes Post. She is a South Bay native and majored in print journalism at Cal State University Long Beach. Julie covers breaking news, crime, and community events with a niche in civic news and feature pieces. Julie also previously worked for CBS in the Los Angeles market as a video journalist.
Thanks for reading CBS NEWS.
Create your free account or log in
for more features.
Author: Richard Wells
Last Updated: 1702164962
Views: 972
Rating: 3.9 / 5 (89 voted)
Reviews: 94% of readers found this page helpful
Name: Richard Wells
Birthday: 1930-02-08
Address: USNS Rasmussen, FPO AP 59102
Phone: +3817225988539570
Job: Article Writer
Hobby: Archery, Motorcycling, Bird Watching, Basketball, Beer Brewing, Rock Climbing, Calligraphy
Introduction: My name is Richard Wells, I am a apt, unswerving, honest, forthright, variegated, persistent, accessible person who loves writing and wants to share my knowledge and understanding with you.